| Address:
|
14282 FRANKLIN AVE
|
| City: |
TUSTIN |
|
State: |
CA |
|
Zip Code: |
92780 |
| Telephone: |
714-508-6000 |
|
Description of Business
|
Primary SIC Code:
2834 |
| (As filed with the SEC)
|
|
|
We are a clinical-stage biopharmaceutical company driven to develop and
manufacture first-in-class monoclonal antibodies for the treatment of cancer and
viral infections. As we advance toward our goal of bringing new therapeutic
options to patients, we plan to execute the following strategies:
· Leverage our phosphatidylserine ("PS")-targeting platform, including our lead
PS-targeting antibody bavituximab, to develop first-in-class antibodies to
treat a broad range of cancer and viral infections;
· Advance three later-stage Phase II clinical programs for bavituximab and
Cotara® in different indications, all representing significant unmet medical
needs for patients;
· Explore additional oncology indications and therapeutic combinations for
bavituximab by offering a cost-effective investigator-sponsored trials ("IST")
program; and ... More ... |
| Date |
12-mos
Rolling EPS |
Dividend |
P/E
Ratio |
| 10/2011 | -0.56 | NA | N/E | | 07/2011 | -0.53 | NA | N/E | | 04/2011 | -0.56 | NA | N/E | | 01/2011 | -0.57 | NA | N/E | | 10/2010 | -0.46 | NA | N/E | | 07/2010 | -0.39 | NA | N/E | | 04/2010 | -0.30 | NA | N/E | | 01/2010 | -0.20 | NA | N/E |
Key Financial Ratios and Statistics |
FYE:
04/30 |
| Profitability |
2011 |
Leverage |
2011 |
| Net Inc/Comm Equity | -0.11 | Total Liab/Total Assets | 0.56 | | Net Inc/Total Assets | -0.98 | Total Liab/Inv Cap | 1.23 | | Net Inc/Inv Cap | -2.17 | Total Liab/Comm Equity | 0.06 | | Pretax Inc/Net Sales | -2.53 | Interest Coverage Ratio | -65.18 | | Net Inc/Net Sales | -2.53 | Curr Debt/Equity | 0.09 | | Cash Flow/Net Sales | -1.96 | LTD/Equity | NA | | SG&A/NetSales | 0.85 | Total Debt/Equity | 0.09 |
| Asset Utilization
|
|
Liquidity |
|
| Net Receivables Turnover | 8.10 | Quick Ratio | 1.44 | | Inventory Turnover | 1.74 | Current Ratio | 1.74 | | Inventory Day Sales | 0.00 | Net Rec/Curr Assets | 0.05 | | Net Sales/Work Cap | 1.03 | Inv/Curr Assets | 0.17 | | Net Sales/PP&E | 6.11 | | |
Income Statement (Millions) |
| |
10/31/2011
|
7/31/2011
|
4/30/2011
|
1/31/2011
|
|
Total Revenues(Net Sales)
|
4.23
|
5.66
|
2.73
|
2.88
|
|
Cost of Goods Sold
|
3.72
|
3.02
|
1.41
|
1.73
|
|
Selling & Admin Exps
|
2.73
|
2.93
|
3.27
|
2.95
|
|
Operating Income
|
-12.04
|
-8.05
|
-9.95
|
-8.84
|
|
Interest Exp
|
0.03
|
0.05
|
0.08
|
0.11
|
|
Pretax Income
|
-12.06
|
-8.09
|
-10.01
|
-8.93
|
|
Other Income
|
0.01
|
0.01
|
0.02
|
0.02
|
|
Net Income Bef Extraordinary ...
|
NA
|
NA
|
NA
|
NA
|
|
Net Income
|
-12.06
|
-8.09
|
-10.01
|
-8.93
|
|
Assets
|
10/31/2011
|
7/31/2011
|
4/30/2011
|
1/31/2011
|
|
Cash & Short Term Investments
|
18.06
|
16.54
|
23.08
|
24.07
|
|
Receivables - Total
|
1.19
|
1.09
|
1.48
|
2.46
|
|
Inventories - Total
|
3.18
|
4.48
|
5.28
|
3.92
|
|
Total Current Assets
|
23.55
|
22.96
|
30.82
|
31.80
|
|
Net Property, Plant & Equipment
|
2.54
|
2.44
|
2.21
|
2.23
|
|
Total Assets
|
27.28
|
27.02
|
34.77
|
35.41
|
|
Liabilities
|
|
|
|
|
|
Accounts Payable
|
8.17
|
7.28
|
7.79
|
6.61
|
|
Debt in Current Liabilities
|
0.33
|
0.83
|
1.32
|
1.81
|
|
Total Current Liabilities
|
13.34
|
13.79
|
17.68
|
16.66
|
|
Long-Term Debt
|
NA
|
NA
|
0.00
|
0.00
|
|
Total Liabilities
|
14.78
|
15.22
|
19.35
|
17.65
|
|
Stockholder's Equity
|
|
|
|
|
|
Minority Interest
|
NA
|
NA
|
NA
|
NA
|
|
Preferred Stock
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Common Stock
|
0.08
|
0.07
|
0.07
|
0.07
|
|
Retained Earnings
|
-316.15
|
-304.10
|
-296.01
|
-285.99
|
|
Treasury Stock
|
NA
|
NA
|
NA
|
NA
|
|
Total Stockholders' Equity
|
12.50
|
11.80
|
15.42
|
17.76
|
|
Total Liabilities and Stockholders' Equity
|
27.28
|
27.02
|
34.77
|
35.41
|
Cash Flow Summary (Millions) |
|
Categories
|
10/31/2011
|
7/31/2011
|
4/30/2011
|
1/31/2011
|
|
Net Cash Provided by Operating Activities
|
-9.38
|
-9.27
|
-7.00
|
-6.73
|
|
Net Cash Provided by Investing Activities
|
-0.55
|
-0.33
|
-0.31
|
-0.29
|
|
Net Cash Provided by Financing Activities
|
11.44
|
3.07
|
6.32
|
13.82
|
Annual Summary Data (Millions) |
| Year |
Sales |
Net
Income |
EPS |
| 04/2007 | 3.71 | -20.80 | -- | | 04/2008 | 6.09 | -23.18 | -- | | 04/2009 | 18.15 | -16.52 | -- | | 04/2010 | 27.94 | -14.49 | -0.30 | | 04/2011 | 13.49 | -34.15 | -0.56 | | Growth Rates | 38.11 | -- | -- |
| Type |
Date(Q,M) |
No.
Owners |
Shares
Held (000s) |
%
Own |
| Institutional | 12/31/11 | 59 | 13,516 | 15.57 |
|
Report Date :
1/30/2012
 Copyright
2012, EDGAR Online, Inc. All
rights reserved. Replication or redistribution of EDGAR Online, Inc. content is
expressly prohibited without the prior written consent of EDGAR Online, Inc.
EDGAR Online, Inc. shall not be liable for any errors or delays in the content,
or for any actions taken in reliance thereon.
|
|
|